ICU Medical, Inc. (NASDAQ:ICUI) Receives $192.80 Consensus Target Price from Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $192.80.

Several equities analysts have commented on the company. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Piper Sandler upped their price objective on shares of ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Raymond James Financial reiterated a “strong-buy” rating and issued a $200.00 target price on shares of ICU Medical in a research note on Friday, August 7th. Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a report on Monday, June 15th. Finally, KeyCorp boosted their target price on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st.

Insiders Place Their Bets

In related news, insider Ben Sousa sold 2,250 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the transaction, the insider owned 3,076 shares of the company’s stock, valued at approximately $548,512.32. The trade was a 42.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daniel Woolson sold 5,417 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $181.33, for a total transaction of $982,264.61. Following the transaction, the vice president owned 17,062 shares of the company’s stock, valued at approximately $3,093,852.46. The trade was a 24.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 16,974 shares of company stock valued at $3,085,844. Corporate insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP acquired a new stake in ICU Medical in the 2nd quarter valued at $26,000. Hilton Head Capital Partners LLC acquired a new position in ICU Medical during the fourth quarter worth $32,000. Public Employees Retirement System of Ohio bought a new position in shares of ICU Medical during the second quarter valued at $51,000. Covestor Ltd lifted its holdings in shares of ICU Medical by 22.1% during the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 126 shares during the period. Finally, Strs Ohio boosted its stake in shares of ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Down 2.5%

ICUI stock opened at $182.53 on Friday. The firm has a market cap of $4.56 billion, a PE ratio of 154.69, a PEG ratio of 2.37 and a beta of 0.74. ICU Medical has a 1 year low of $112.50 and a 1 year high of $192.85. The company has a fifty day simple moving average of $160.03 and a 200 day simple moving average of $142.86. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same period last year, the company earned $2.10 earnings per share. The business’s revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Sell-side analysts anticipate that ICU Medical will post 7.19 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.